Specialization in Oncology, Where Unmet Medical Needs Are High
First written in FY2024-Q3. 4 of 5 entries say "Restated". Latest entry: 2026-10-15.
3 other companies' latest entry also says "Restated".
- 2026-10-15RestatedEarnings
「アンメットメディカルニーズの高いがん領域に特化して事業を進めています。」
アンメットメディカルニーズの高いがん領域に特化する方針が再確認された。 - FY2026-H1RestatedAnnual report
「Our vision is to grow into a Japan-originated pharmaceutical company focused on research and development by 2030, and we are pursuing a business focused on cancer, where unmet medical needs are high.」
The policy of focusing the business on cancer, where unmet medical needs are high, continues. - FY2025-H1RestatedAnnual report
「Specifically, we are pursuing drug discovery research focused on cancer, where unmet medical needs are high.」
The policy of concentrating R&D on cancer, where unmet medical needs are high, continues. - FY2024RestatedAnnual report
「Our principal business is the research and development of innovative small-molecule drugs with novel mechanisms of action, or first-in-class drugs, in cancer, where medical needs, including unmet medical needs, are high.」
The policy of concentrating R&D on cancer, where unmet medical needs are high, continues. - FY2024-Q3First statedAnnual report
「We are pursuing drug discovery research focused on cancer, where unmet medical needs are high.」
A policy of limiting the company’s R&D focus to cancer has been stated.